2. Search Result
Search Result
Results for "

low molecular weight heparin

" in MedChemExpress (MCE) Product Catalog:

14

Inhibitors & Agonists

3

Peptides

1

Isotope-Labeled Compounds

1

Oligonucleotides

Targets Recommended:
Art. -Nr. Produktname Target Forschungsgebiete Chemical Structure
  • HY-109509
    Enoxaparin
    1 Publications Verification

    PK 10169; Enoxaparin sodium

    		 Factor Xa Thrombin SARS-CoV Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    Enoxaparin (PK 10169), a low-molecular-weight heparin (LMWH) derivative. Enoxaparin exerts anticoagulant activity through antithrombin III, an endogenous inhibitor of factor Xa and thrombin IIa. Enoxaparin protect the rat hippocampus against TBI (traumatic brain injury) via antioxidant and anti-inflammatory properties. Enoxaparin can be used for the research of deep vein thrombosis (DVT), pulmonary embolism, TBI and COVID-19 .
    Enoxaparin
  • HY-P2839
    Heparinase

    heparinase I

    		 Endogenous Metabolite Metabolic Disease
    Heparinase (Heparinase I) degrades heparin to oligosaccharide or unsaturated disaccharide. Heparinase can be used in the preparation of low molecular weight heparin (LMWH) .
    Heparinase
  • HY-100897
    Sulodexide

    		Thrombin Cardiovascular Disease
    Sulodexide is a mixture of glycosaminoglycans available in soft capsule form for oral administration. It is composed of low molecular weight heparin (80%) and dermatan sulfate (20%). Sulodexide exhibits antithrombotic activity through interaction with antithrombin III (AT III) and heparin cofactor II (HC II), and inhibition of thrombin formation. Sulodexide exhibits profibrinolytic activity through release of tissue plasminogen activator (tPA). Sulodexide exhibits endothelial protective and anti-inflammatory effect, ameliorates chronic venous disease . Sulodexide is a glycosaminoglycan mixture available in soft gelatin capsule form for oral administration.
    Sulodexide
  • HY-100897A
    Sulodexide solution

    		Thrombin Cardiovascular Disease
    Sulodexide solution is a mixture of glycosaminoglycans that can be administered by injection. It is composed of low molecular weight heparin (80%) and dermatan sulfate (20%). Sulodexide exhibits antithrombotic activity through interaction with antithrombin III (AT III) and heparin cofactor II (HC II), and inhibition of thrombin formation. Sulodexide exhibits profibrinolytic activity through release of tissue plasminogen activator (tPA). Sulodexide exhibits endothelial protective and anti-inflammatory effect, ameliorates chronic venous disease.
    Sulodexide solution
  • HY-P2953
    Heparitin sulfate lyase

    heparinase III

    		 Glycosidase Cancer
    Heparitin sulfate lyase (Heparinase III) is a glycosidic lyase targeting heparan sulfate and heparin. Heparitin sulfate lyase is promising for research of low-molecular-weight heparin production and cancers .
    Heparitin sulfate lyase
  • HY-P5107
    Low molecular weight protamine

    LMWP; TDSP5

    		 VEGFR Cancer
    Low molecular weight protamine (LMWP;TDSP5) is a truncated arginine-rich protamine peptide, as well as a heparin/low-molecular-weight heparin antidote and a cell-penetrating delivery carrier. Low molecular weight protamine neutralizes heparin-induced anticoagulant activities, including aPTT, anti-Xa and anti-IIa activities, and also neutralizes anti-Xa activity of commercially available low-molecular-weight heparin preparations. Low molecular weight protamine translocates across mammalian cell membranes, delivers conjugated impermeable molecules across tumor tissues, enhances skin permeability of conjugated epidermal growth factor, and accelerates wound healing when conjugated with epidermal growth factor. Low molecular weight protamine retains the in vitro cell proliferation activity of conjugated EGF, and also enables site-specific conjugation with peptides or proteins via genetic recombination. Low molecular weight protamine can be used in studies related to colon adenocarcinoma, skin wounds and diabetic skin wounds .
    Low molecular weight protamine
  • HY-18660
    Ciraparantag

    PER977

    		 Factor Xa Thrombin Cardiovascular Disease
    Ciraparantag (PER977) is a thrombin and factor Xa inhibitor. Ciraparantag is a broad-spectrum reversal agent for anticoagulants, including low-molecular-weight heparin, unfractionated heparin, and certain direct oral anticoagulants. It is reported to antagonize the effects of all coagulants except VKAs and agratroban .
    Ciraparantag
  • HY-P5107A
    Low molecular weight protamine acetate

    LMWP acetate; TDSP5 acetate

    		 VEGFR Cancer
    Low molecular weight protamine acetate (LMWP acetate;TDSP5 acetate) is a truncated arginine-rich protamine peptide, which also acts as an antidote for heparin/low molecular weight heparin and a cell-penetrating delivery vector. Low molecular weight protamine acetate neutralizes heparin-induced anticoagulant activities, including aPTT, anti-Xa and anti-IIa activities. Low molecular weight protamine acetate translocates across mammalian cell membranes, delivers conjugated impermeable molecules through tumor tissues, enhances the skin permeability of conjugated epidermal growth factor, and accelerates wound healing when conjugated with epidermal growth factor. Low molecular weight protamine acetate retains the in vitro cell proliferation activity of conjugated EGF, and also enables site-specific conjugation with peptides or proteins via genetic recombination. Low molecular weight protamine acetate can be used in studies related to colon cancer, skin wounds and diabetic skin wounds .
    Low molecular weight protamine acetate
  • HY-105240
    Delparantag

    PMX-60056

    		 Factor Xa Cardiovascular Disease
    Delparantag (PMX-60056) is a salicylamide derivative and an effective unfractionated heparin (UFH) and low molecular weight heparin (LMWH) reversing agent. Delparantag shows ability to neutralize the anticoagulation and bleeding effects of UFH and LMWH .
    Delparantag
  • HY-18660B
    Ciraparantag acetate

    PER977 acetate

    		 Factor Xa Thrombin Cardiovascular Disease
    Ciraparantag (PER977) acetate is a thrombin and factor Xa inhibitor. Ciraparantag acetate is a broad-spectrum reversal agent for anticoagulants, including low molecular weight heparins, unfractionated heparins, and some direct oral anticoagulants, but not VKAs .
    Ciraparantag acetate
  • HY-157930
    TP-2

    		Biochemical Assay Reagents Cardiovascular Disease
    TP-2, a caltrop-like multicationic small molecule, is an antidote that can completely neutralize both unfractionated heparin (UFH) and low-molecular-weight heparins (LMWHs). TP-2 is not only superior to protamine, has higher neutralization activity, but is also biocompatible .
    TP-2
  • HY-18660A
    Ciraparantag TFA

    PER977 TFA

    		 Factor Xa Thrombin Cardiovascular Disease
    Ciraparantag (PER977) TFA is a thrombin and factor Xa inhibitor. Ciraparantag TFA is a broad-spectrum reversal agent for anticoagulants, including low-molecular-weight heparin, unfractionated heparin, and certain direct oral anticoagulants. It is reported to antagonize the effects of all coagulants except VKAs and agratroban .
    Ciraparantag TFA
  • HY-18660S
    Ciraparantag-d8 (tetra(hydrochloride) diacetate)

    PER977-d8 tetrahydrochloride diacetate

    		 Isotope-Labeled Compounds Factor Xa Thrombin Cardiovascular Disease
    Ciraparantag-d8 (PER977-d8) tetrahydrochloride diacetate is the deuterium labeled Ciraparantag (HY-18660). Ciraparantag is a thrombin and factor Xa inhibitor. Ciraparantag is a broad-spectrum reversal agent for anticoagulants, including low-molecular-weight heparin, unfractionated heparin, and certain direct oral anticoagulants. It is reported to antagonize the effects of all coagulants except VKAs and agratroban .
    Ciraparantag-d8 (tetra(hydrochloride) diacetate)
  • HY-180988
    Heparin reversal agent-1

    		Biochemical Assay Reagents Cardiovascular Disease
    Heparin reversal agent-1 (Compound QA-1) is a reversal agent for Heparin (HY-17567). Heparin reversal agent-1 shows neutralization activity. Heparin reversal agent-1 completely reverses the anticoagulant activity of both unfractionated heparin and low-molecular-weight heparins, including Dalte, Enoxa, and Nadro .
    Heparin reversal agent-1

Online-Anfrage

Your information is safe with us. * Required Fields.

Anrede

  

Country or Region *

Name des Antragstellers *

 

Name der Organisation *

Department *

     

E-Mail-Addresse *

 

Produktname *

Art. -Nr.

  

Requested quantity *

Telefonnummer *

     

Bemerkungen

Online-Anfrage

Inquiry Information

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent: